NCT03914768 — Shenzhen Geno-Immune Medical Institute cancer vaccine trial
Immune Modulatory DC Vaccine Against Brain Tumor
Registry record
| Registry ID | NCT03914768 ↗ |
|---|---|
| Lead sponsor | Shenzhen Geno-Immune Medical Institute |
| Collaborators | — |
| Phase | Phase 1 |
| Status | Not Yet Recruiting |
| Indication | Diffuse Intrinsic Pontine Glioma or Glioblastoma |
| Enrollment | 10 participants (target) |
| Start date | 2026-12-31 |
| Primary completion | 2029-05-31 (est.) |
| Last registry update | 26 Aug 2026 |
Every field above is mirrored from the study record on ClinicalTrials.gov (NCT03914768), which the sponsor maintains and which carries the full protocol summary, eligibility criteria, sites and contacts. No neoantigen vaccine is approved anywhere yet — every program here is investigational, and inclusion is not an endorsement. See the methodology for how the tracker is built.
Where this fits
Daily coverage of the modality, tumor type and players this study touches:
Related trials
FAQ
What phase is NCT03914768?
NCT03914768 (Immune Modulatory DC Vaccine Against Brain Tumor) is registered on ClinicalTrials.gov as Phase 1, sponsored by Shenzhen Geno-Immune Medical Institute.
Is NCT03914768 recruiting?
As of the 2026-08-26 registry update, NCT03914768 is listed as "Not Yet Recruiting". Eligibility criteria, study sites and contacts are maintained by the sponsor on the ClinicalTrials.gov record.
Who is running NCT03914768?
The lead sponsor is Shenzhen Geno-Immune Medical Institute.
What condition does NCT03914768 study?
The registered condition is Diffuse Intrinsic Pontine Glioma or Glioblastoma. Primary completion is listed as 2029-05-31 (estimated).
Are results available for NCT03914768?
neoag.ai mirrors the registry's factual fields — sponsor, phase, status and dates — and does not publish trial results. Any posted results, publications, or outcome measures appear on the ClinicalTrials.gov record for NCT03914768.
Back to the full neoantigen vaccine trial tracker — 107 studies, refreshed daily from ClinicalTrials.gov. Background: primer, glossary, and the companies landscape.